Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel application of recombinant hCREG glycoprotein and application thereof on coronary stent

A glycoprotein, coronary artery technology, applied to the new use of recombinant hCREG glycoprotein, the application field of coronary stent, can solve the problem of limited research work on CREG protein, to promote endothelial cell repair and growth, inhibit atherosclerosis , the effect of solving restenosis

Pending Publication Date: 2017-02-22
GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY +1
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, its other applications have not yet been targeted. So far, the research work on CREG protein at home and abroad is very limited.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel application of recombinant hCREG glycoprotein and application thereof on coronary stent
  • Novel application of recombinant hCREG glycoprotein and application thereof on coronary stent
  • Novel application of recombinant hCREG glycoprotein and application thereof on coronary stent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0051] The preparation of embodiment 1 recombinant hCREG glycoprotein

[0052] The preparation method of described recombinant hCREG glycoprotein comprises the following steps:

[0053] (1) Construction of the recombinant gene vector: RT-PCR technique was used to amplify the hCREG open reading frame of the stop codon mutation, and the hCREG RT-PCR primers of the stop codon mutation were as follows: the upstream primer was 5'-aa ggatcc atggccgggctatcccgc-3'( SEQ ID NO.2), the downstream primer is: 5'-gc gaattc Gcactgaactgtgacatttaatattcttctgg-3' (SEQ ID NO.3), wherein. Capital letters represent the stop codon of C / G mutation, construct the recombinant human CREG protein expression vector pcDNA3.1-his / myc-hCREG with his tag protein, and the recombinant hCREG glycoprotein contains as shown in SEQ ID NO.1 The amino acid sequence of is as follows:

[0054] MAGLSRGSARALLAALLASTLLALLVSPARGRGGRDHGDWDEASRLPPLPPREDAARVARFVTHVSDWGALATISTLEAVRGRPFADVLSLSDGPPGAGSGVPYFYLSPLQLSVSNLQENPYATL...

Embodiment 2

[0058] Example 2 Preparation of recombinant hCREG glycoprotein coronary stent

[0059] The nano-microporous bare metal stent of Lepu (Beijing) Medical Devices Co., Ltd. was used. The 316L stainless steel bare metal stent was corroded with 38% hydrochloric acid for 12 hours and then corroded with 28% hydrochloric acid for 5 minutes under the action of an electric field. Nanopores of 100-800nm ​​are prepared on the surface of the scaffold.

[0060] Using the CREG protein prepared in Example 1, use a sodium carbonate buffer solution with a pH of 9.6 (0.05mol / L) to prepare the CREG protein into a coating buffer solution of 1.6 mg / mL, and put the nanoporous bare metal stent into the preparation The good coating buffer solution was taken out after soaking for 48 hours, freeze-dried in a vacuum dryer at -55°C, and stored at 4°C.

[0061] The scanning electron micrograph of the prepared recombinant hCREG glycoprotein coronary stent is shown in FIG. 1 , and it can be seen that a large...

Embodiment 3

[0062] Example 3 Preparation of drug-protein combined scaffold

[0063] Nanoporous bare metal stents were prepared according to the method in Example 2.

[0064] Prepare rapamycin drug with a concentration of 1% in acetone solution. A balloon is used to protect the inner surface of the stent, and rapamycin drug is sprayed on the outer surface of the stent.

[0065] The sodium carbonate buffer solution with pH of 9.6 (0.05mol / L) was used to prepare CREG glycoprotein into a coating buffer of 1.6 mg / mL, put the nanoporous bare metal stent into the prepared coating buffer, soak for 48 After 1 hour, it was taken out, freeze-dried in a vacuum dryer at -55°C, and stored at 4°C.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of biology, relates to the field of medical apparatuses and instruments and in particular to novel application of a recombinant hCREG glycoprotein and application thereof on a coronary stent. The recombinant hCREG glycoprotein disclosed by the invention is used for preparing a pharmaceutical composition capable of inhibiting inflammations and / or inhibiting atherosclerosis. The recombinant hCREG glycoprotein disclosed by the invention is capable of maintaining the advantages of the existing drug eluting stent, inhibiting development of atherosclerosis and promoting blood vessel reendothelialization, and has important clinical significances for solving the problems that restenosis is caused by new atherosclerosis of the existing coronary stent and patients need to take antithrombotic and antiplatelet drug after the operation.

Description

technical field [0001] The invention belongs to the field of biotechnology and relates to the field of medical devices, in particular to a new application of recombinant hCREG glycoprotein and its application on coronary stents. Background technique [0002] In the past two decades, coronary stents have been widely used to treat vascular occlusive diseases. However, in-stent restenosis and long-term medication after surgery reduce the surgical benefit of percutaneous coronary intervention (PCI). How to effectively prevent and control restenosis and improve the quality of life of patients after PCI is a huge challenge for medical workers. [0003] Studies have shown that damage to vascular endothelial function and excessive proliferation / migration of vascular smooth muscle cells are important links in the occurrence of restenosis. Therefore, the drug-eluting stent (drug-eluting stent, DES) loaded with vascular smooth muscle cell proliferation inhibitors (rapamycin and its a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17A61P29/00A61P9/10A61P7/02A61L31/16A61L31/10A61L31/14
CPCA61K38/1709A61L31/10A61L31/146A61L31/16A61L2300/252A61L2300/41A61L2300/606C08L89/00
Inventor 韩雅玲邓婕孙鸣宇陈永强
Owner GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com